Skip to content

Pompe Disease Registry Protocol

Glycogen Storage Disease Type II | Pompe Disease

The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.

The objectives of the Registry are:

* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

All patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and/or documentation of 2 GAA gene mutations.

Exclusion Criteria:

There are no exclusion criteria in this Registry

Study Location

Investigational Site Number : 124010
Investigational Site Number : 124010
Vancouver, British Columbia
Canada

Contact Study Team

Investigational Site Number : 124007
Investigational Site Number : 124007
Hamilton, Ontario
Canada

Contact Study Team

Investigational Site Number : 124018
Investigational Site Number : 124018
Montreal, Quebec
Canada

Contact Study Team

Investigational Site Number : 124002
Investigational Site Number : 124002
Edmonton, Alberta
Canada

Contact Study Team

Investigational Site Number : 124022
Investigational Site Number : 124022
Moncton, New Brunswick
Canada

Contact Study Team

Investigational Site Number : 124004
Investigational Site Number : 124004
Montreal, Quebec
Canada

Contact Study Team

Investigational Site Number : 124011
Investigational Site Number : 124011
Vancouver, British Columbia
Canada

Contact Study Team

Investigational Site Number : 124021
Investigational Site Number : 124021
London, Ontario
Canada

Contact Study Team

Investigational Site Number : 124001
Investigational Site Number : 124001
Sherbrooke, Quebec
Canada

Contact Study Team

Investigational Site Number : 124014
Investigational Site Number : 124014
Calgary, Alberta
Canada

Contact Study Team

Investigational Site Number : 124019
Investigational Site Number : 124019
Winnipeg, Manitoba
Canada

Contact Study Team

Investigational Site Number : 124006
Investigational Site Number : 124006
Toronto, Ontario
Canada

Contact Study Team

Study Sponsored By
Sanofi
Participants Required
More Information
Study ID: NCT00231400